EP0419462A4 - Improved immunotoxin therapies utilizing purified ricin a-chain species - Google Patents

Improved immunotoxin therapies utilizing purified ricin a-chain species

Info

Publication number
EP0419462A4
EP0419462A4 EP19880906547 EP88906547A EP0419462A4 EP 0419462 A4 EP0419462 A4 EP 0419462A4 EP 19880906547 EP19880906547 EP 19880906547 EP 88906547 A EP88906547 A EP 88906547A EP 0419462 A4 EP0419462 A4 EP 0419462A4
Authority
EP
European Patent Office
Prior art keywords
chain species
therapies utilizing
utilizing purified
improved immunotoxin
purified ricin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19880906547
Other versions
EP0419462A1 (en
Inventor
Patrick J. Scannon
Russell T. Kawahata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of EP0419462A1 publication Critical patent/EP0419462A1/en
Publication of EP0419462A4 publication Critical patent/EP0419462A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19880906547 1987-07-17 1988-07-12 Improved immunotoxin therapies utilizing purified ricin a-chain species Ceased EP0419462A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7482487A 1987-07-17 1987-07-17
US74824 1987-07-17

Publications (2)

Publication Number Publication Date
EP0419462A1 EP0419462A1 (en) 1991-04-03
EP0419462A4 true EP0419462A4 (en) 1991-07-17

Family

ID=22121901

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880906547 Ceased EP0419462A4 (en) 1987-07-17 1988-07-12 Improved immunotoxin therapies utilizing purified ricin a-chain species

Country Status (4)

Country Link
EP (1) EP0419462A4 (en)
NZ (1) NZ225372A (en)
WO (1) WO1989000583A1 (en)
ZA (1) ZA885124B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
JP4163251B2 (en) * 1992-09-24 2008-10-08 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Group B Streptococcus Type II and Type V Polysaccharide-protein conjugate vaccine
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005309A1 (en) * 1987-01-27 1988-07-28 Xoma Corporation Potentiation of cytotoxic conjugates
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481946A (en) * 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4612007A (en) * 1981-06-16 1986-09-16 Edelson Richard Leslie Method and system for externally treating the blood
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4689401A (en) * 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005309A1 (en) * 1987-01-27 1988-07-28 Xoma Corporation Potentiation of cytotoxic conjugates
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8900583A1 *

Also Published As

Publication number Publication date
EP0419462A1 (en) 1991-04-03
WO1989000583A1 (en) 1989-01-26
NZ225372A (en) 1991-04-26
ZA885124B (en) 1989-04-26

Similar Documents

Publication Publication Date Title
GB2210924B (en) Cable tie
GB2211106B (en) Manipulating means
ZA881769B (en) Recombinant ricin toxin fragements
GB8806643D0 (en) Genetic manipulation
GB8301788D0 (en) Impact-action self-propelled mechanism
GB2208349A (en) Tie
ZA885124B (en) Improved immunotoxin therapies utilizing purified ricin a-chain species
GB2203154B (en) Immunoglobulin conjugates
GB8325378D0 (en) Impact-action self-propelled mechanism
ZW12688A1 (en) Conduit construction means
DE3265065D1 (en) Carding bar
GB8718420D0 (en) Ore purification
GB2266833B (en) Improvements relating to tobacco reconstitution
GB8728749D0 (en) Pipe wrapping material
GB8408961D0 (en) Bale transporter
GB9210471D0 (en) Improvements relating to tobacco reconstitution
GB8709221D0 (en) Immunotoxins
GB2213173B (en) Tie
IE871890L (en) Protein immunotoxins
GB8730109D0 (en) Improvements in/relating to pipe-end protectors
IE841526L (en) Immunotoxin conjugates
CA59243S (en) Saddle
GB2089414B (en) Gardeners' line
GB8716006D0 (en) Conduit
ZA881715B (en) Immunoglobulin conjugates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910528

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940123